First of all, the stem cell content in placenta is huge, and the stem cell content in placenta accounts for 85%-9% in perinatal tissues of newborns, and the rest is in umbilical cord and umbilical cord blood. Secondly, the placenta is one of the four immune special zones of human body, with low immunogenicity and super immunoregulation. Storing the placenta of one child can benefit the whole family.

Up to now, 9 of the 1 stem cell drugs approved in the world are related to mesenchymal stem cells. Mesenchymal stem cells from placenta have been involved in more than 1 diseases, including systemic lupus erythematosus, rheumatoid arthritis and other immune system diseases. Neurological diseases such as Parkinson's disease and Alzheimer's disease, as well as orthopedic diseases such as cartilage injury and osteoarthritis, make placental stem cells a treasure house of life and health.

In p>216, Boya stem cells and the Third Hospital of Beijing Medical University jointly conducted the world's first treatment of premature senility with placental stem cells, which attracted worldwide attention. Boya stem cells, Gulou Hospital affiliated to Nanjing University and Affiliated Hospital of Jiangsu University carried out hundreds of clinical trials using placental mesenchymal stem cells to treat systemic lupus erythematosus, and achieved good clinical results. The clinical research won the first prize of scientific and technological progress in Jiangsu Province.

In the future, the futility of placental stem cells will naturally be broken by more clinical research and application of placental stem cells, which is also the inevitable trend of regenerative medicine development. The function of placental storage of stem cells also indicates that a 4G technology revolution is taking place in the field of stem cells.